Your email has been successfully added to our mailing list.

×
0.0035552682611506 0.00420168067226888 0.00484809308338716 0.00549450549450543 0.00646412411118291 0.00678733031674211 0.00791855203619913 0.00937297996121523
Stock impact report

FDA grants full approval for Roche's Avastin for treatment-resistant brain cancer [Seeking Alpha]

ROCHE HOLDING LTD S/ADR (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
Company Research Source: Seeking Alpha
FDA grants full approval for Roche's Avastin for treatment-resistant brain cancerRoche (OTCQX:RHHBY) unit Genentech's Avastin (bevacizumab) is nowfully approved in the U.S. for the treatment of adults with glioblastoma that has progressed after prior therapy. The FDA previously granted provisional approval under its accelerated approval provision.Now read:3 Things In Biotech You Should Learn Today: November 20, 2017 » Show less Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for RHHBY alerts
Opt-in for
RHHBY alerts

from News Quantified
Opt-in for
RHHBY alerts

from News Quantified